secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001558370-23-002996
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics reports record Q4 2022 revenue $18.2M (+21% YoY); full year $65.2M
------------------------------------------------------------------------------

- Q4 revenue $18.2M, up 21% YoY; US treatment session revenue record $12.5M.
- Full year net loss ($37.2M) or ($1.38) per share vs ($31.2M) or ($1.22) in 2021.
- Cash $70.3M at year-end; guides Q1 2023 revenue $15-16M, FY2023 $66-72M.
- Expanded Greenbrook partnership through 2028; NGS policy allows NPs to order TMS.
- Peer-reviewed publication shows NeuroStar TMS effective for anxious depression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/0001558370-23-002996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/stim-20230307x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer